Skip to content
10-K

Annual Report

TScan Therapeutics, Inc. TCRX

0001193125-26-089884

← back to feed
Filed
Mar 4, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 129.78M sh
Shares Diluted FY 2025 · Dec 31, 2024 111.99M sh
Capex FY 2025 · Dec 31, 2025 $4.41M
Capex FY 2025 · Dec 31, 2024 $3.83M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$135.32M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$110.82M
Long Term Debt FY 2025 · Dec 31, 2025 $32.53M
Long Term Debt FY 2025 · Dec 31, 2024 $32.07M
Cash And Equivalents FY 2025 · Dec 31, 2025 $152.41M
Cash And Equivalents FY 2025 · Dec 31, 2024 $178.69M
Stockholders Equity FY 2025 · Dec 31, 2025 $123.12M
Stockholders Equity FY 2025 · Dec 31, 2024 $240.97M
Stockholders Equity FY 2025 · Dec 31, 2023 $150.87M
Current Liabilities FY 2025 · Dec 31, 2025 $18.7M
Current Liabilities FY 2025 · Dec 31, 2024 $35.96M
Total Liabilities FY 2025 · Dec 31, 2025 $105.67M
Total Liabilities FY 2025 · Dec 31, 2024 $130.15M
Current Assets FY 2025 · Dec 31, 2025 $157.21M
Current Assets FY 2025 · Dec 31, 2024 $292.72M
Total Assets FY 2025 · Dec 31, 2025 $228.79M
Total Assets FY 2025 · Dec 31, 2024 $371.12M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.00
Eps Diluted FY 2025 · Dec 31, 2024 −$1.14
Eps Basic FY 2025 · Dec 31, 2025 −$1.00
Eps Basic FY 2025 · Dec 31, 2024 −$1.14
Sga Expense FY 2025 · Dec 31, 2025 $31.99M
Sga Expense FY 2025 · Dec 31, 2024 $30.29M
Rd Expense FY 2025 · Dec 31, 2025 $114.15M
Rd Expense FY 2025 · Dec 31, 2024 $107.35M
Net Income FY 2025 · Dec 31, 2025 −$129.77M
Net Income FY 2025 · Dec 31, 2024 −$127.5M
Operating Income FY 2025 · Dec 31, 2025 −$135.81M
Operating Income FY 2025 · Dec 31, 2024 −$134.82M
Revenue FY 2025 · Dec 31, 2025 $10.33M
Revenue FY 2025 · Dec 31, 2024 $2.82M